Trehalose

Generic Name: Trehalose

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₂O_₁₁

CAS Number: 99-20-7

Unique Ingredient Identifier: B8WCK70T7I

Background: Cabaletta has been used in trials studying the treatment of Oculopharyngeal Muscular Dystrophy.

Clinical Trials

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

Phase 4

Not yet recruiting

Conditions: Dry Eye Disease (DED)

Interventions: Drug: 3% trehalose

First Posted Date: 2024-10-23

Last Posted Date: 2025-03-13

Lead Sponsor: Southern California College of Optometry at Marshall B. Ketchum University

Target Recruit Count: 30

Registration Number: NCT06655441

Locations: 🇺🇸
Marshall B. Ketchum University, Fullerton, California, United States

The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammatory Markers

Phase 4

Not yet recruiting

Conditions: Dry Eye
Dry Eye Syndromes
Cataract

Interventions: Dietary Supplement: Omega-3
Drug: Trehalose
Drug: Zocular Eyelid System Treatment
Other: Blephadex cleansing eyelid wipes

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Uptown Eye Specialists

Target Recruit Count: 68

Registration Number: NCT05990712

Locations: 🇨🇦
Uptown Eye, Brampton, Ontario, Canada

Intermediate-Sized Expanded Access Study

Conditions: Amyotrophic Lateral Sclerosis

First Posted Date: 2022-10-28

Last Posted Date: 2024-04-24

Lead Sponsor: Seelos Therapeutics, Inc.

Registration Number: NCT05597436

Locations: 🇺🇸
Hospital for Special Care, New Britain, Connecticut, United States
🇺🇸
Holy Cross Hospital - Phil Smith Neuroscience Institute, Fort Lauderdale, Florida, United States
🇺🇸
Nova Southeastern University, Fort Lauderdale, Florida, United States

and more 14 locations

Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

Early Phase 1

Recruiting

Conditions: Type 2 Diabetes
Healthy Aging

Interventions: Drug: Trehalose
Drug: Placebo

First Posted Date: 2022-10-25

Last Posted Date: 2024-05-31

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 60

Registration Number: NCT05593549

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Phase 2

Terminated

Conditions: Spinocerebellar Ataxia Type 3

Interventions: Drug: SLS-005
Drug: Placebo

First Posted Date: 2022-08-05

Last Posted Date: 2024-04-24

Lead Sponsor: Seelos Therapeutics, Inc.

Target Recruit Count: 23

Registration Number: NCT05490563

Locations: 🇺🇸
Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
🇩🇪
University Hospital of Leipzig, Leipzig, Saxonia, Germany

and more 20 locations

Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease

Phase 4

Conditions: Parkinson Disease

Interventions: Drug: Trehalose

First Posted Date: 2022-05-02

Last Posted Date: 2022-05-02

Lead Sponsor: Neuromed IRCCS

Target Recruit Count: 20

Registration Number: NCT05355064

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: SLS-005
Drug: Matching Placebo

First Posted Date: 2021-11-29

Last Posted Date: 2025-05-14

Lead Sponsor: Merit E. Cudkowicz, MD

Target Recruit Count: 161

Registration Number: NCT05136885

Locations: 🇺🇸
Healey Center for ALS at Mass General, Boston, Massachusetts, United States

Phase IV Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy (PRK)

Phase 4

Completed

Conditions: Photorefractive Keratectomy
Corneal De-epithelialization

Interventions: Drug: Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%
Drug: Sodium Hyaluronate Ophthalmic 0.4%

First Posted Date: 2021-01-11

Last Posted Date: 2024-04-03

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 88

Registration Number: NCT04704518

Locations: 🇲🇽
Aris Vision Institute de Guadalajara, S. C., Guadalajara, Jalisco, Mexico

Mycose AdminiStration for HealIng Alzheimer NEuropathy (MASHIANE)

Phase 1

Conditions: Alzheimer Disease

Interventions: Drug: Trehalose

First Posted Date: 2020-12-11

Last Posted Date: 2020-12-11

Lead Sponsor: Mashhad University of Medical Sciences

Target Recruit Count: 20

Registration Number: NCT04663854

Locations: 🇮🇷
Ghaem Educational, Research and Treatment Center, Mashhad, Razavi Khorasan, Iran, Islamic Republic of

Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose

Phase 2

Withdrawn

Conditions: Oculopharyngeal Muscular Dystrophy

Interventions: Drug: Trehalose

First Posted Date: 2020-01-13

Last Posted Date: 2020-01-13

Lead Sponsor: Bioblast Pharma Ltd.

Registration Number: NCT04226924

Locations: 🇨🇦
Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada
🇨🇦
Ecogene-21, Chicoutimi, Quebec, Canada
🇨🇦
CHU de Québec-Université Laval- Hôpital Enfant-Jésus, Québec, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy